ABSTRACT
Crush injuries to the foot have become increasingly prevalent in contemporary settings, primarily arising from incidents such as the impact of large objects falling onto the foot or involvement in traffic accidents. The complexity of treating these injuries is compounded by the intricate anatomy of the foot. In specific scenarios, the implementation of an integrated management approach could prove advantageous. In this report, we depict the case of a 23-year-old male who visited the Shalya OPD with a wound on his left foot caused by trauma. The wound covered the medial portion of the foot, involving the dorsal area, and measured roughly 20 cm by 9 cm and was unable to walk. We successfully managed the case by adopting an integrative approach. The Ayurvedic treatment included Panchavalkala kashaya for wound irrigation, as well as oral administration of Amalaki rasayana, Triphala guggulu, Shatavari churna and Ashwagandha churna. Jatyadi taila was topically applied. For the first seven days, in addition to these ayurvedic medications, we also employed analgesics and antibiotics to treat infection and pain. To accomplish early closure, we employed a split-thickness skin graft after sufficient granulation tissue had appeared. The wound was completely healed within three months and the patient was able to walk freely without any support. The combined approach yielded a promising result in this case.
ABSTRACT
The diversity in the biological response of 4-thiazolidinones has attracted the attention of many researchers to explore this framework for its potential. It is, therefore, of prime importance that the study of this topic and the development of new synthetic strategies should be based on the most recent knowledge, emerging from the latest research. This review is an endeavor to highlight the progress in the chemistry and biological activity of the 4-thiazolidinones, predominantly after 2006. The last section of the review encompasses the various patents granted on 4-thiazolidinone analogs/derivatives with World Intellectual Proprietary Organization (WIPO) and United State Patent Trademark Office (USPTO), particularly in the duration of the year 2000 to the year 2012.
Subject(s)
Anti-Infective Agents/pharmacology , Anticonvulsants/pharmacology , Antihypertensive Agents/pharmacology , Antineoplastic Agents/pharmacology , Hypoglycemic Agents/pharmacology , Thiazolidines/pharmacology , Animals , Anti-Infective Agents/chemical synthesis , Anti-Infective Agents/chemistry , Anticonvulsants/chemical synthesis , Anticonvulsants/chemistry , Antihypertensive Agents/chemical synthesis , Antihypertensive Agents/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Humans , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/chemistry , Molecular Structure , Stereoisomerism , Thiazolidines/chemical synthesis , Thiazolidines/chemistryABSTRACT
Despite modern techniques, the recurrence rate of Urolithiasis is approximately 50% within 5 years. Thus, there must be some drug that corrects the metabolic errors and prevents the formation of stone. In Ayurveda, a detailed description of urolithiasis is mentioned under the heading of Ashmari. A group of Ayurvedic drugs are described for the management of Urolithiasis, like Pashanbheda (Bergenia ligulata), Varuna (Crataeva nurvala), Kullattha (Dolichos biflorus), Gokshur (Tribulus terrestris), etc. in our ancient texts. The present work was designed to study the effect of Varuna (Crataeva nurvala) on the experimental model of urolithiasis (albino rats). The study was categorized into two groups: Group I, treated and Group II, control. In all albino rats, stone was surgically implanted into the urinary bladder. Estimation of the urinary and serum electrolyte done periodically and x-rays were exposed at a regular interval. This study suggests the decoction of Varuna (Crataeva nurvala) is effective in the management of urolithiasis.
